Success Story: Double Success Story! Our Expert Team Secured NIW & EB1A Approval for A Senior Biostatistician from China
On July 18th, 2023, and February 7th, 2025, we received another I-140 NIW (National Interest Waiver) and EB1A (Alien of Extraordinary Ability) Approvals for a Senior Biostatistician in the Field of Biostatistics (Approval Notice).
General Field: Biostatistics
Position at the Time of Case Filing: Senior Biostatistician
Country of Origin: China
State of Residence at the Time of Filing: Georgia
Approval Notice Date: July 18th, 2023 & February 7th, 2025 (NIW&EB1A)
Processing Time: 8 days (NIW – Premium Processing Requested), and 12 months, 26 days (EB1A)
Case Summary:
We are pleased to share the approval of both the EB-2 NIW (National Interest Waiver) and EB1A (Alien of Extraordinary Ability) petitions for a biostatistics expert specializing in time-to-event data analysis and advanced statistical methodologies for cancer research. At the time of filing, the client was employed as a senior biostatistician in the pharmaceutical industry and had already demonstrated significant influence on clinical trial design, cancer treatment strategies, and medical imaging research.
Research Focus and Contributions:
The client’s proposed endeavor focused on advancing statistical models for drug development and clinical trial methodologies to improve cancer prognosis and treatment outcomes. His research addresses some of the most critical challenges in public health, including accurate prediction of patient outcomes, risk stratification, and optimization of clinical trial design.
Research Impact and Scientific Recognition:
To demonstrate the national and international significance of his work, the petitions highlighted several key indicators:
- Publications: 8 peer-reviewed journal articles in selective, high-impact journals.
- Citations: His work has been cited 220 times in scholarly research worldwide, with multiple papers ranking among the most highly cited in their category.
- Peer Review: The client has conducted at least 20 reviews for respected journals, reflecting the recognition of his expertise in validating the work of other scientists.
- Funding Support: His research has been supported by the National Institutes of Health (NIH), underlining the importance of his contributions to advancing healthcare.
Support from Experts in the Field:
The EB1A petition was further strengthened by four recommendation letters from distinguished experts, including independent scholars from top institutions. These letters praised his innovations in statistical modeling for oncology and emphasized that his work has shaped ongoing advances in cancer prognosis and clinical trial efficiency.
“His outstanding scientific investigations have major significance for guiding treatment regimens and the continued involvement of [Client] in scientific inquiry is necessary for advancing the fight against cancer. It is therefore important that he be allowed to continue his research in the United States.”
Well Positioned to Advance the Proposed Endeavor:
With a Ph.D. in biostatistics and a professional record bridging academia and the pharmaceutical industry, the client is uniquely equipped to continue pioneering work in medical statistics. His methodological advances are directly applicable to oncology research, drug development, and trial optimization, fields of clear national and global importance.
Approval and Outcome:
After securing NIW approval in 2023, the client also obtained EB1A approval in February 2025, despite the higher scrutiny applied to extraordinary ability cases. Both approvals reflect his standing as a recognized authority in biostatistics and his proven capacity to benefit the United States through research-driven advancements in cancer treatment and clinical trial methodology. NAILG is proud to have successfully represented this client and looks forward to his continued impact on improving healthcare outcomes.